Caricamento...
miR-134 increases the antitumor effects of cytarabine by targeting Mnks in acute myeloid leukemia cells
The relapse and resistance to cytarabine (Ara-C) therapy is still a dominating obstacle to the successful clinical treatment of acute myeloid leukemia (AML). Recent studies have shown that dysregulation of miRNAs might modulate the resistance of cancer cells to anticancer drugs; yet, the mechanism i...
Salvato in:
| Pubblicato in: | Onco Targets Ther |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5975600/ https://ncbi.nlm.nih.gov/pubmed/29872325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S143465 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|